Table 1 Patient disposition by treatment group.

	Placebo (n (%))	Exisulind 200 mg (n (%))	Exisulind 400 mg (n (%))	Total
Total No of patients enrolled	95	91	95	281
Hyperplastic polyps*	41	43	42	126
ITT population (adenomatous polyps only)	54	48	53	155
Discontinued prematurely†	11 (20.4)	10 (20.8)	20 (37.7)	41
Efficacy evaluable population	43 (79.6)	38 (79.2)	33 (62.3)	114

*Patients with histologically confirmed hyperplastic polyps were excluded from the per study protocol.

†Reasons for discontinuation included adverse events, consent withdrawal, protocol violation, and other (among 155 patients with adenoma).

ITT, intention to treat.